Global News and Digital Insights
for the Healthcare Industry

Eli Lilly may expand tirzepatide’s usage to weight loss treatment

After Eli Lilly’s tirzepatide, a medicine for diabetes type 2, showed weight loss characteristics, the company is now eyeing to explore it as a weight loss medication. Tirzepatide’s weight loss potential was talk of the town after the firm presented at the American Diabetes Association’s (ADA) 82nd Scientific Sessions. Though Lilly has not yet put forth its future agenda regarding this medication, they do claim to remain accessible to the consumers as needed.

Read More at Pharmaceutical Technology

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn